Inclusion Criteria:

- have histologically or cytologically confirmed metastatic malignant melanoma.

- have measurable disease.

- have failed at least one prior treatment for metastatic disease or not considered a
candidate for standard first line treatment.

- have not received previous carboplatin and/or paclitaxel chemotherapy.

- have NO continuing acute toxic effects of any prior radiotherapy, chemotherapy, or
surgical procedures.

- any surgery involving the melanoma (except biopsies) must have occurred at least 28
days prior to study enrolment.

- be at least 18 years of age.

- have received NO chemotherapy, radiotherapy, immunotherapy or hormonal therapy within
28 days prior to receiving study drug

- have ECOG Performance Score of ≤ 2.

- have a life expectancy of at least 3 months.

- absolute neutrophil ≥ 1.5 x 10^9; Platelets ≥ 100 x10^9; Hemoglobin ≥ 9.0 g/dL; Serum
creatinine ≤ 1.5 x upper limit of normal (ULN); Bilirubin ≤ 1.5 x ULN; AST/ALT ≤ 2.5
x ULN.

- negative pregnancy test for females with childbearing potential.

- be willing and able to comply with scheduled visits, the treatment plan, and
laboratory tests.

Exclusion Criteria:

- receive concurrent therapy with any other investigational anticancer agent while on
study.

- be good candidate for surgery with curative intent for metastatic disease.

- have a history of or current evidence of brain metastasis(es).

- be on immunosuppressive therapy or have known HIV infection or active hepatitis B or
C.

- be a pregnant or breast-feeding woman.

- have clinically significant cardiac disease.

- have dementia or altered mental status that would prohibit informed consent.

- have any other acute, or chronic medical or psychiatric condition or laboratory
abnormality that may increase the risk associated with study participation or study
drug administration or may interfere with the interpretation of study results and, in
the judgment of the Principal Investigator, would make the patient inappropriate for
this study.